World journal of otorhinolaryngology - head and neck surgery · 2026
Thai Translation and Validation of Chronic Rhinosinusitis-Patient Reported Outcome (CRS-PRO).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chitsuthipakorn Wirach, Pooldum Vorachai, Phetpong Juthaporn, Lawpoolsri Saranath, Kanjanawasee Dichapong, Kowatanamongkon Patlada, Mongkolkul Kittichai, Seresirikachorn Kachorn, Snidvongs Kornkiat
Аннотация
OBJECTIVES: The Chronic Rhinosinusitis Patient-Reported Outcome (CRS-PRO) questionnaire was recently developed for use in chronic rhinosinusitis (CRS) patients. This instrument was developed using current diagnostic criteria. This study aimed to translate and validate CRS-PRO for Thai CRS patients.
METHODS: The three-phase translation process and validation were conducted at Rajavithi Hospital, a tertiary hospital in Bangkok, Thailand. Adults (> 18 years) with primary CRS, diagnosed using EPOS2020 criteria, were recruited alongside non-CRS controls. Discriminant validity was assessed by comparing scores between CRS patients and non-CRS controls. Concurrent validity was evaluated by correlating CRS-PRO with the Thai version of the Sinonasal Outcome Test-22 (SNOT-22). Reliability was assessed using internal consistency (Cronbach's alpha) and test-retest reliability using intraclass correlation coefficient (ICC).
RESULTS: A total of 85 CRS patients and 40 non-CRS controls were enrolled. The Thai CRS-PRO was completed in (101.80 ± 26.36) seconds. CRS patients had significantly higher scores than controls (16 [10-24] vs. 2 [0-5], p < 0.001) (median [IQR]). CRS-PRO demonstrated strong concurrent validity with SNOT-22 (ρ = 0.82, p < 0.001), high internal consistency (Cronbach's alpha = 0.89), and high test-retest reliability (ICC = 0.81, 95% confidence interval 0.72-0.88).
CONCLUSIONS: The Thai-translated CRS-PRO has been developed and validated. It demonstrated significant discriminant validity between patients and non-patients, a very strong correlation with the Thai version of SNOT-22, and good reliability. Its brevity and time efficiency support its applicability in both clinical practice and research, enhancing its potential for widespread adoption.
METHODS: The three-phase translation process and validation were conducted at Rajavithi Hospital, a tertiary hospital in Bangkok, Thailand. Adults (> 18 years) with primary CRS, diagnosed using EPOS2020 criteria, were recruited alongside non-CRS controls. Discriminant validity was assessed by comparing scores between CRS patients and non-CRS controls. Concurrent validity was evaluated by correlating CRS-PRO with the Thai version of the Sinonasal Outcome Test-22 (SNOT-22). Reliability was assessed using internal consistency (Cronbach's alpha) and test-retest reliability using intraclass correlation coefficient (ICC).
RESULTS: A total of 85 CRS patients and 40 non-CRS controls were enrolled. The Thai CRS-PRO was completed in (101.80 ± 26.36) seconds. CRS patients had significantly higher scores than controls (16 [10-24] vs. 2 [0-5], p < 0.001) (median [IQR]). CRS-PRO demonstrated strong concurrent validity with SNOT-22 (ρ = 0.82, p < 0.001), high internal consistency (Cronbach's alpha = 0.89), and high test-retest reliability (ICC = 0.81, 95% confidence interval 0.72-0.88).
CONCLUSIONS: The Thai-translated CRS-PRO has been developed and validated. It demonstrated significant discriminant validity between patients and non-patients, a very strong correlation with the Thai version of SNOT-22, and good reliability. Its brevity and time efficiency support its applicability in both clinical practice and research, enhancing its potential for widespread adoption.